IP Library › Granted Patent US 10,449,189
Granted Patent B2
US 10,449,189 · App. 15/574,060 · Granted Oct 22, 2019

Therapeutic agent for fibrosis

Inventor: Akio Fujioka (Tsukuba, JP)
Assignee: TAIHO PHARMACEUTICAL CO., LTD.
A61K31/47A61P11/00C07D215/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,449,189
App. No.
15/574,060
Granted
Oct 22, 2019
Kind
B2
Abstract

Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.

Claims (12)

1. A method for treating fibrosis, comprising:

administering 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof to a patient.

2. The method of claim 1 , wherein the fibrosis is idiopathic lung fibrosis.

3. The method of claim 1 , wherein the fibrosis is lung fibrosis.

4. The method of claim 1 , wherein the fibrosis is interstitial pneumonia accompanied by fibrillation.

5. The method of claim 1 , wherein the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is intra-tracheally administered to the patient.

6. The method of claim 1 , wherein the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is orally administered to the patient.

7. The method of claim 1 , wherein the salt is a methanesulfonate salt.

8. The method of claim 1 , wherein the salt is a monomethanesulfonate salt.

9. The method of claim 3 , wherein the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is intra-tracheally administered to the patient.

10. The method of claim 1 , wherein 0.005 to 5,000 mg of the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is administered to the patient.

11. The method of claim 1 , wherein 0.01 to 1,000 mg of the 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof is administered to the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2017
From: FUJIOKA, AKIO
To: TAIHO PHARMACEUTICAL CO., LTD.
Reel/Frame 044123/0763 →
Priority Claims (1)
JP 2015-127788 · Jun 25, 2015 · national
Continuity (1)
Related Publication 20180289690A1 · Oct 11, 2018
Cited By (1)
US 12,280,045